去势抵抗性前列腺癌AR位点改变图谱与临床层级
该研究整合1751例mCRPC患者的3048份血浆cfDNA及配对白细胞DNA,使用靶向捕获面板全面刻画AR位点改变。84%患者检出体细胞AR改变,AR突变占19.7%,并建立基于治疗反应的AR基因型功能层级,其中ALTR4重排显著影响AR通路抑制剂疗效。
要点
- 84%的mCRPC检出体细胞AR改变,AR突变占19.7%且常为亚克隆。
- ALTR4重排受强正向选择并显著影响AR通路抑制剂疗效。
- 约16%的mCRPC未检出AR改变,对AR通路抑制剂应答较好。
核心结论
- 本研究建立了迄今最全面的mCRPC AR位点体细胞改变图谱,并确立AR基因型的临床相关性。
研究设计与样本
- 研究整合来自8项临床试验和1个区域生物样本库的1751例mCRPC患者,共3048份血浆cfDNA及配对白细胞DNA样本。
- 样本使用多代定制靶向杂交捕获面板测序,覆盖AR位点及71个前列腺癌基因。
主要发现
- 84%的mCRPC检出体细胞AR改变,其分布受TP53和DNA修复缺陷等底层基因组影响。
- Wnt突变肿瘤呈现独特的AR扩增结构,偏好整合替代下游增强子且拷贝数低。
- AR突变存在于19.7%的mCRPC中,常为亚克隆,并在仅AR增强子获得的肿瘤中富集。
- 研究基于治疗反应建立AR基因型的功能层级,并鉴定出在intron 4或exon 4截断配体结合域的ALTR4重排。
- 约16%的mCRPC缺乏可检测的AR改变,ETS基因融合频率降低,且许多对AR通路抑制剂表现出稳健应答。
临床怎么用
- 对mCRPC患者进行AR位点全面基因分型,有助于预判AR通路抑制剂疗效。
- 识别ALTR4重排可提示AR通路抑制剂耐药风险。
- 无AR改变的mCRPC患者可能对AR通路抑制剂应答较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Somatic alterations to the androgen receptor (AR) gene are pivotal drivers of treatment resistance in metastatic castration-resistant prostate cancer (mCRPC), but their prevalence, clinical impact, and etiology remain incompletely understood. PATIENTS AND METHODS: We assembled a meta-cohort of 3048 plasma cell-free DNA and matched leukocyte DNA samples from 1751 mCRPC patients, accrued from eight clinical trials and a regional biobank. Samples were sequenced with successive generations of a custom targeted hybridization capture panel with extensive coverage of the AR locus and 71 prostate cancer genes, enabling comprehensive characterization of AR genotypes including enhancer and gene copy number amplification, and mutations or structural rearrangements. RESULTS: Somatic AR alterations, detected in 84% of mCRPC, were shaped by underlying genomics, including TP53 and DNA repair defects. Wnt-mutant tumors showed unique AR amplification structures characterized by preferential incorporation of an alternative downstream enhancer and low copy number. AR mutations were present in 19.7% of mCRPC, often subclonal, and enriched in tumors with AR enhancer-only gain. We establish a functional hierarchy of AR genotypes based on treatment responses and identify a specific class of AR rearrangements truncating the ligand-binding domain within intron 4 or exon 4 (ALTR4) that are under robust positive selection and strongly impact AR pathway inhibitor outcomes, distinct from other rearrangements arising as byproducts of AR amplification. We provide evidence that a subset of AR amplifications arise through breakage-fusion-bridge cycles with associated Xq loss. Some 16% of mCRPC lacked detectable AR alterations and had reduced frequency of ETS gene fusions, with many demonstrating robust responses to AR pathway inhibitors. CONCLUSIONS: This study provides the most comprehensive resource to date characterizing somatic alterations at the AR locus. Our clinicogenomic analysis establishes the repertoire and clinical relevance of AR genotypes in mCRPC, informing efforts to target renewed AR dependency.
引用
- Virtanen T, Kwan EM, Parekh K, et al. Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer. Ann Oncol. 2025. PMID: 41161480. doi:10.1016/j.annonc.2025.10.1236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。